Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

  • Technology appraisal guidance
  • TA1099
  • Published: 
The timelines for this appraisal have been revised slightly. The committee meeting will now be held on 12 June 2025.